Intellia Therapeutics (United States)
- Research works
- 26 ▲ 748% vs 2013–17
- Citations
- 1.4k 54.2 per fractional work
- Top-10% rate
- 10.5% record average 16.5%
- Open access
- 48% world 28%
Not ranked overall: Intellia Therapeutics (United States) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Biochemistry, Genetics and Molecular Biology, 9.9×. Every wedge is a field page.
Which keywords describe research at Intellia Therapeutics (United States)?
By fractional works in all years, weighted toward what it does more of than the world: Genome Engineering, RNA-Guided, Cancer Immunotherapy, Immunotherapy, CAR T Cells, Chimeric Antigen Receptor, Gene Therapy and Genomic Integration.
- Reprogramming
- Differentiation
- Transcriptional Regulation
- Kinin Receptor Family
- Embryonic Stem Cells
- Genomic Integration
- Chimeric Antigen Receptor
- Immunotherapy
- RNA-Guided
- Genome Engineering
- Cancer Immunotherapy
- CAR T Cells
- Gene Therapy
- AAV
- Hereditary Angioedema
- Pluripotent Stem Cells
- Viral Vectors
- Induced Pluripotent Stem Cells
Size is fractional works in all years in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 18 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 18 words, with their numbers
- Genome Engineering5▲ 323×1 topic
- RNA-Guided5▲ 323×1 topic
- Cancer Immunotherapy4▲ 113×2 topics
- Immunotherapy4▲ 24×2 topics
- CAR T Cells4▲ 352×1 topic
- Chimeric Antigen Receptor4▲ 352×1 topic
- Gene Therapy2▲ 31×3 topics
- Genomic Integration1▲ 53×2 topics
- AAV1▲ 74×1 topic
- Embryonic Stem Cells1▲ 65×2 topics
- Hereditary Angioedema1▲ 169×1 topic
- Kinin Receptor Family1▲ 169×1 topic
- Pluripotent Stem Cells1▲ 67×2 topics
- Transcriptional Regulation1▲ 18×2 topics
- Viral Vectors1▲ 74×1 topic
- Differentiation1▲ 57×2 topics
- Induced Pluripotent Stem Cells1▲ 118×1 topic
- Reprogramming1▲ 118×1 topic
Which research topics does Intellia Therapeutics (United States) publish most on?
By volume in 2022–2025: CRISPR and Genetic Engineering, CAR-T cell therapy research, Virus-based gene therapy research and Pluripotent Stem Cells Research.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 CRISPR and Genetic Engineering Molecular Biology 4 works
- 2 CAR-T cell therapy research Oncology 2 works
- 3 Virus-based gene therapy research Genetics 1 works
- 4 Pluripotent Stem Cells Research Molecular Biology 1 works
- 5 Monoclonal and Polyclonal Antibodies Research Radiology, Nuclear Medicine and Imaging 0 works
- 6 Neurogenetic and Muscular Disorders Research Genetics 0 works
- 7 Organ Transplantation Techniques and Outcomes Surgery 0 works
- 8 Viral Infectious Diseases and Gene Expression in Insects Molecular Biology 0 works
- 9 Renal Transplantation Outcomes and Treatments Transplantation 0 works
- 10 MicroRNA in disease regulation Cancer Research 0 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Intellia Therapeutics (United States)'s research output changed?
Output in 2018–2022 was 748% higher than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Cambridge
- Harvard University
- Massachusetts Institute of Technology
- Center for Astrophysics Harvard & Smithsonian
- National Bureau of Economic Research
- IIT@MIT
- World Wide Web Consortium
- Broad Institute
- Smithsonian Astrophysical Observatory
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.